(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
In summary, there are many animal models that are useful in selecting new antiarrhythmic drugs. The selection of which model is most idea depends upon precisely what question is being asked. The large number of experimental models used to evaluate antiarrhythmic compounds points out the inability of anyone model to define the probability of antiarrhythmic efficacy in man. It has therefore become standard practice to utilize a batter of animal models for the evaluation of new antiarrhythmic agents. Each model has its own advantages and disadvantages and it is necessary to understand each model fully in oder to evaluate experimental findings and apply them to clinical settings. We believe that the availability of the chronic myocardial infarction ventricular tachyarrhythmia model provides 1) an excellent opportunity to more precisely understand arrhythmia mechanisms, 2) to develop new techniques such as signal averaging for evaluating late low level potentials identifying hearts at high risk of sudden death 3) to identify new antifibrillatory drugs versus drugs that are effective primarily against PVC's and ventricular tachycardia 4) to identify new surgical techniques to eliminate VT/VF, and 5) to evaluate new pacing modalities including implantable cardioverters. Although all animal models are wrong, many are very useful in furthering our knowledge directed at decreasing the distressingly high mortality from heart disease. NORMAL HtART TACHYCMDIA HtART , .. '" \ I I I I I I I I I .
Contents:
I Basic Considerations.- 1 What animal models are useful in selecting new antiarrhythmic drugs?.- 2 How to test for antiarrhythmic drugs.- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients?.- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs?.- Panel Discussion: Basic considerations.- II Status of Specific Antiarrhythmic Agents.- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol - efficacy in the treatment of ventricular arrhythmias: current status and controversies.- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents.- 7 Class IC antiarrhythmic agents: status - 1984.- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias.- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol.- Panel Discussion: Status of specific antiarrhythmic agents.- III Special Considerations and FDA Standards.- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice.- 11 Use of a computer in the new drug evaluation process.- 12 Sudden cardiac death - failure or effect of antiarrhythmic drug therapy?.- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs.- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models?.- Panel Discussion: Special considerations and FDA standards.- IV New Antiarrhythmic Devices.- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic?.- 16 Pacing for ventricular tachycardia.- 17 Termination of ventricular tachycardia by transvenous cardioversion.- 18 The automatic implantable cardioverter/defibrillator.- 19 New antiarrhythmia devices - FDA's requirements for effectiveness.- Panel Discussion: New antiarrhythmic devices.- V Evaluation Of Atrial Arrhythmias.- 20 Study designs to evaluate atrial arrhythmias are easy.- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection.- 22 Approaches to drug selection and serial drug testing.- Panel Discussion: Evaluation of atrial arrhythmias.- Participants.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: October, 2011
Pages: 356
Weight: 569g
Availability: Available
Subcategories: Cardiovascular Medicine
From the same series
Jean-Claude Tardif
Xander H T Wehrens
Johan H. C. Reiber
Raimund Erbel
M.P. Sambhi
Pedro Brugada
W. Bleifeld
Naranjan S. Dhalla
Bohuslav Ostadal
Ralph Shabetai
Jason X.-J. Yuan
Hein J.J. Wellens
R. C. Becker
Franz H. Messerli
C.H. Peels
Stephen M. Factor
Hiroyuki Suga
Hugo Ector
Brian E. Jaski
Richard A. Walsh
Seymour Glagov
Michiel J. Janse
Lloyd W. Klein
Thomas H Marwick
Ernst E. van der Wall
P.J. Walter
Ernst E. van der Wall
Ernst E. van der Wall
A-M. Salmasi
Michel Emile Safar
A-M. Salmasi
Ernst E. van der Wall
Andrea Natale
Albert de Roos
C.A. Nienaber
Guillem Pons-Llado
Vinzenz Hombach
R. Vos
J. Candell-Riera
R.W. Stout
Peter Hanrath
Johan H. C. Reiber
P.A.F.M. Doevendans
Jack Rychik
P.A.F.M. Doevendans
P.E. Vardas
Makoto Nagano
George D. Dangas
Myrvin H. Ellestad
C.J. Preusse
Thomas H Marwick
Thomas H Marwick
Ernst E. van der Wall
G.T. Meester
A.G. Herman
J.C. Tardif
P.J. Walter
Johan H. C. Reiber
Ernst E. van der Wall
Lloyd W. Klein
Akira Matsumori
Robert L. Wilensky
Bernard Swynghedauw
Juan Carlos Kaski
Franz H. Messerli
John F. Keaney Jr.
Keith L. March
Naranjan S. Dhalla
Zainul Abedin
Juan Carlos Kaski
Eric J Topol
A.V. Bruschke
Richard C. Becker
J. Candell-Riera
Ghassan Bkaily
Lionel H. Opie
Bernard Swynghedauw
Geoffrey Burnstock
P. Cummins
Nicholas Sperelakis
Mina Rajskina
A.A. Knowlton
Johan H. C. Reiber
Irene D. Turpie
J. A. E. Spaan
Ernst E. van der Wall
Masatsugu Hori
Bing Liem Liong
R. Fagard
M. Iwase
R. Stroobandt
A.V. Bruschke
David M. Mirvis
Franz H. Messerli
G. Assmann
Melvin Scheinman
J. Morganroth
J.W. de Jong
M.B. Rosenbaum
C. Tissa Kappagoda
H.V. Villareal
J. Morganroth
Ernst E. van der Wall
Naranjan S. Dhalla
H. Mitchell Perry Jr.
M.P. Spencer
Henk Keurs
C.T. Lancée
J.R. Roelandt
G.S. Wagner
H. Kesteloot
A.C. Arntzenius
Johan H. C. Reiber
A. Maseri
Michel Emile Safar
M.P. Spencer
W. Bleifeld
Henk Keurs
Willem H. Birkenhager
Antonio Bayes de Luna
J.R. Roelandt
Naranjan S. Dhalla
H. Rijsterborgh
Marianne J. Legato
Naranjan S. Dhalla
S. Chien
Rafael Beyar
H.E. Van Dam
M.P. Spencer
J.R. Roelandt
Hilbert J.Th. Thalen
C. Marchesi
J.P.M Hamer
Rafael Beyar
L.N. Bouman
A. Alboni
Douglas P. Zipes
Nicholas Sperelakis
Borys Surawicz
Antonio Bayes de Luna
Johan H. C. Reiber
Hein J.J. Wellens
J.V. Chapman
E. Aliot
Vinzenz Hombach
Michael R. Rosen
William H. Gaasch
Pawan K. Singal
Robert Plonsey
H.L. Stone
J. Soler-Soler
Ernst E. van der Wall
Michel Emile Safar
Hein J.J. Wellens
J.R. Roelandt
Vinzenz Hombach
Richard S. Meltzer
Marvin A. Konstam
Naranjan S. Dhalla
Naranjan S. Dhalla
S.N. Willich
Johan H. C. Reiber
C.A. Nienaber
Ernst E. van der Wall
Robert J. Siegel
Markus Schwaiger
Andrew Wechsler
Elliot Rapaport
Naranjan S. Dhalla
John E. Tooke
Derek Yellon
Henk Keurs
Steve M. Teague
J.W. de Jong
Naranjan S. Dhalla
Nicholas Sperelakis
P.H. Heintzen
J. Morganroth
John B. Lombardini
Adam Schneeweiss
J.R. Roelandt
Naranjan S. Dhalla
Naranjan S. Dhalla
J.C. Chatham
Pim J. de Feyter
David W. Holt
Catherine A. Neill
J. Roelandt
A.P. Shepherd
Gastone Leonetti
Nico H.J. Pijls
K. Robinson
P.A.F.M. Doevendans
Douglas P. Zipes
Jose Marin-Garcia
Jonathan S. Steinberg
Francisco Villarreal
Dick Macdonald
Ragavendra R. Baliga
Dick Macdonald